Macrogenics (MGNX) Prepaid Assets (2012 - 2026)
Macrogenics (MGNX) posted quarterly Prepaid Assets of $8.4 million for Q1 2026, up 4.93% year-over-year from $8.0 million in Q1 2025, and down 4.28% quarter-over-quarter from $8.7 million in Q4 2025.
Analysis
Macrogenics (MGNX) Prepaid Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Prepaid Assets for 15 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 4.93% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 4.93% YoY), while the FY2025 annual figure was $8.7 million, down 24.05% from the prior year.
- Prepaid Assets fell to $8.4 million in Q1 2026 per MGNX's latest filing, from $8.7 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $14.7 million in Q1 2022 and bottomed at $6.5 million in Q2 2023.
- Historically, Prepaid Assets has averaged $9.5 million across 5 years, with a median of $9.3 million in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets slumped 52.0% — and 2024, when it jumped 43.21%.
- Macrogenics' Prepaid Assets stood at $10.2 million in 2022, then declined by 2.12% to $9.9 million in 2023, then advanced by 15.77% to $11.5 million in 2024, then dropped by 24.05% to $8.7 million in 2025, then retreated by 4.28% to $8.4 million in 2026.
- Business Quant data shows MGNX's Prepaid Assets at $8.4 million in Q1 2026, $8.7 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.21 Mn |
| Mar 31, 2026 | 8.37 Mn |
| Dec 31, 2025 | 7.22 Mn |
| Sep 30, 2025 | 7.71 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | 7.98 Mn |
| Dec 31, 2024 | 11.51 Mn |
| Sep 30, 2024 | 9.84 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Mar 31, 2024 | 9.87 Mn |
| Dec 31, 2023 | 9.95 Mn |
| Sep 30, 2023 | 8.51 Mn |
| Jun 30, 2023 | 6.48 Mn |
| Mar 31, 2023 | 9.72 Mn |
| Dec 31, 2022 | 10.16 Mn |
| Sep 30, 2022 | 9.27 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Mar 31, 2022 | 14.71 Mn |
| Dec 31, 2021 | 21.17 Mn |
| Sep 30, 2021 | 18.06 Mn |